Menu

Final Nail Hammered into NgAgo Coffin

The paper describing the gene-editing method is retracted.

Aug 3, 2017
Kerry Grens

ISTOCK, FSTOP123Following an editorial expression of concern last year, the authors of a study describing a gene-editing method have retracted their paper from Nature Biotechnology. They say that despite the efforts of numerous independent laboratories, their observations could not be replicated.

The editors of Nature Biotechnology praised the process. “[I]t is the wider research community that tests methods, identifies potential sources of error, validates reagents and optimizes assays,” they wrote in an editorial. “In this case, it took dozens of dedicated individuals to work through the details of the published protocol and produce well-documented and controlled refutation studies.”

The original study claimed to have found a competitor for CRISPR genome editing. NgAgo, an Argonaut protein from archaea, could precisely disrupt specified sequences in the human genome, Chunyu Han of Hebei University of Science and Technology in Shijiazhuang, China, and colleagues reported. But replication attempts failed.

“We are therefore retracting our initial report at this time to maintain the integrity of the scientific record,” Han’s team wrote in the retraction notice. “We nevertheless continue to investigate the reasons for this lack of reproducibility with the aim of providing an optimized protocol.”

See “Scientists Can’t Replicate Gene-Editing Method

As Nature points out, Danish biomedical company Novozymes paid an undisclosed amount of money to partner with Hebei. “Scientific research takes time and we’ll continue to look for any technological advances, NgAgo included, that can have a positive impact on our work,” Dongyi Chen, Novozymes’s press manager, tells Nature.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.